New Indications and Products Offset Patent Expirations
SAN FRANCISCO, Sept. 11 /PRNewswire/ -- The U.S. market for drug treatment of major neuropathic pain (NP) conditions is currently valued at $2.6 billion, according to US Neuropathic Pain, a report released today by WWMR, Inc. Growth over the past four years has been driven largely by the successful launch of Lyrica (pregabalin) for diabetic neuropathic pain and post-herpetic neuralgia in December 2004 along with its 2007 approval for fibromyalgia, as well as the launch of Lilly's Cymbalta (duloxetine) for diabetic neuropathic pain in 2004. The additional June 2008 approval of Cymbalta for fibromyalgia will spur penetration of this prevalent condition.
Based on a decade of experience tracking and forecasting the NP Market, WWMR predicts healthy growth over the next 5 years due to penetration of the market for fibromyalgia. Two yet to be launched products, Forest Laboratories/Cypress Biosciences's antidepressant milnacipran and Schwarz Pharma's sodium ion channel antagonist/CRMP2 modulator lacosamide (Vimpat), will compete for market share as well as provide the benefit of an additional mechanism of action. Growth will slow between 2013 and 2018 as Lyrica and Cymbalta patents expire, and the fibromyalgia market penetration becomes saturated. Additional launch of novel compounds and new brands of existing drug classes will be required in order to sustain market growth.
The US neuropathic pain market consists of 4.7 million patients, and is
expected to grow to more than 6.1 million patients, and be valued at $5.1
billion in 2018. With the addition of two key new indications to this
report (Fibromyalgia and Neuropathic Cancer Pain) patient population
estimates and projections as well as market value and projections, are
available for a total of ten Neuropathic Pain Conditions (neuropathic back
pain, fibromyalgia, diabetic neuropathy, neuropathic cancer pain, complex
regional pain sy
|SOURCE WWMR, Inc.|
Copyright©2008 PR Newswire.
All rights reserved